Your Ketamine Patients and Your GLP-1 Patients Are the Same People
A woman books a ketamine series for depression that four antidepressants failed to touch. She weighs more than she wants to. She drinks more than she tells her physician. Six miles away, a different clinic starts her on semaglutide for weight loss. Nobody there asks about her mood. Nobody at the first clinic asks about her weight. She is one patient with one tangled problem, and she is being treated as two.
Treating one patient across two service lines only pays if the overhead on both stays down. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| The overlap is already built | 47 percent of peptide clinics offer a named GLP-1 drug, based on our review of 846 clinic menus |
| The patients overlap too | Depression, problem drinking and metabolic disease cluster in the same people |
| The science is moving | The VA is testing semaglutide against placebo in more than 600 veterans with alcohol use disorder |
| The gap is screening | Most clinics treat mood or metabolism, and few ask patients about the other |
| The wall is marketing | No GLP-1 is approved for mood or addiction. Say so on your website and you invite enforcement |
The Overlap Is Not Hypothetical
Start with what clinics actually sell. We reviewed the published menus of 846 verified peptide clinics across all 50 states. Semaglutide appears on 39 percent of them. Tirzepatide appears on 29 percent. Counted together, 47 percent offer a named GLP-1 drug.
BPC-157 still leads the category at 55 percent. That surprises people who assume peptide medicine is a weight loss business. It is not. Nearly half these practices, though, now write GLP-1 prescriptions alongside recovery compounds.
The same convergence runs the other direction. Many ketamine practices added weight loss or peptide services over the past two years. Two very different clinic types are arriving at the same menu.
The Patients Were Always Shared
Clinicians have known the pattern for decades. Depression and obesity co-occur. Alcohol use disorder and depression co-occur. Metabolic disease tracks with both.
Nobody needs a study to see this in a waiting room. What has changed is that one drug class may touch several of those conditions at once.
Why Researchers Think the Drugs Cross Over
GLP-1 receptors are not confined to the pancreas and gut. They also appear in brain regions that govern reward and motivation. The leading hypothesis is straightforward. A drug that dampens the pull of food may dampen other appetites too.
Evidence so far comes largely from patient records. People taking GLP-1 medications show lower rates of alcohol and substance use disorders than similar patients on other diabetes drugs. That is a correlation, and correlations from records carry real limits.
The test is now underway. The VA began recruiting in late July for a randomized trial of semaglutide in more than 600 veterans with alcohol use disorder. Results will take time. The question is no longer fringe.
What Peptide Clinics Are Missing
Consider the weight loss patient who is not losing weight. She misses doses. She plateaus. She stops answering follow up calls.
Untreated depression explains a share of those cases. So does heavy drinking, which adds calories and erodes adherence. A GLP-1 program that never screens for either will keep losing patients and never learn why.
Our review of patient inquiries found that people ask by goal rather than by compound. They want to feel like themselves again. That sentence belongs as much to psychiatry as to metabolic medicine.
What Ketamine Clinics Are Missing
The blind spot mirrors it. Interventional psychiatry screens carefully for mood, suicidality and prior medication trials. Metabolic health rarely enters intake.
Yet weight, sleep apnea and heavy drinking all shape how a patient responds to treatment and whether the response holds. A practice that already runs a GLP-1 line has the tools on site. Most simply never connect the two charts.
The Wall You Cannot Cross
Here is the boundary, and it is firm. No GLP-1 drug is approved to treat depression, anxiety, alcohol use disorder or addiction. A trial that started recruiting last week changes nothing about that.
Clinics may screen patients, coordinate care and document outcomes. Clinics may not advertise a weight loss drug as a treatment for drinking or mood. Federal enforcement in this category has consistently gone after website language, a pattern we mapped in our anatomy of an FDA GLP-1 warning letter.
Integrated care is a clinical practice. It is not a marketing claim.
What to Do This Month
Three steps work regardless of how the VA trial reads out.
Screen in both directions. Add a brief alcohol and mood screen to metabolic intake. Add weight, sleep and drinking questions to psychiatric intake. Both take minutes.
Track the dual patients. Flag anyone enrolled in both programs and follow their outcomes as one case. That data does not exist anywhere at scale yet, which is what makes it valuable.
Keep the two conversations separate in public. Talk about comorbidity and coordinated care. Do not talk about treating addiction with a weight loss drug. Clinics weighing the combination for the first time can start with our guide to adding peptide services to a ketamine practice.
